Related Experiment Video

Updated: Aug 6, 2026

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models
06:16

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Published on: March 16, 2022

Anti-angiogenic therapy: Prospects for treatment of ocular tumors

Mark I Rosenblatt1, Dimitri T Azar

  • 1Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA 02114, USA.

Seminars in Ophthalmology
|August 17, 2006
PubMed

Insights

Angiogenesis inhibitors show promise for treating ocular tumors like uveal melanoma and VHL disease. Further clinical trials are needed to confirm the efficacy of these anti-angiogenic therapies in ophthalmology.

Area of Science:

  • Ophthalmology
  • Oncology
  • Vascular Biology

Background:

  • Tumor growth, maintenance, and metastasis depend on angiogenesis, the formation of new blood vessels.
  • The "angiogenic switch" regulates tumor aggressiveness, with pro- and anti-angiogenic factors playing key roles.
  • Angiogenesis inhibitors are established treatments for ocular diseases and are in clinical trials for various cancers.

Purpose of the Study:

  • To review the role of angiogenesis in ocular tumors.
  • To assess the current evidence and potential of angiogenesis inhibitors for treating ocular tumors.
  • To highlight the need for further clinical investigation.

Main Methods:

  • Review of existing literature on angiogenesis in ocular tumors.
  • Analysis of case reports and limited clinical trials involving angiogenesis inhibitors in ocular oncology.
  • Synthesis of evidence regarding the efficacy of anti-angiogenic therapies.

Main Results:

  • Angiogenesis is implicated in the progression of uveal melanoma, retinoblastoma, and von Hippel Lindau (VHL) disease.
  • Limited trials of angiogenesis inhibitors in uveal melanoma and VHL disease show promising outcomes.
  • Current data is primarily based on case reports, necessitating more extensive research.

Conclusions:

  • Angiogenesis inhibitors represent a potential therapeutic strategy for ocular tumors.
  • Promising preliminary results warrant larger, controlled clinical trials to establish efficacy and safety.
  • Further research is crucial to optimize the use of angiogenesis inhibitors in ophthalmology.

More Related Videos

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...